Klin Farmakol Farm. 2023;37(1):29-32 | DOI: 10.36290/far.2023.005
Finerenone: pharmacological profile
- Ústav farmakologie LF UP a FN Olomouc
Finerenone is a non-steroidal mineralocorticoid receptor antagonist. In addition to the highly selective blockade of the overactivation of this receptor in cardiorenal diseases, it also inhibits the activation of specific cofactors involved in the expression of genes involved in the pathophysiology of inflammation, tissue fibrosis and hypertrophy. It thereby affects one of the three major mechanisms of progression of chronic kidney injury in type 2 diabetes. It is administered at a maintenance dose of 20 mg orally once daily. Its bioavailability is about 43%, volume of distribution 53 l, and binding to plasma albumin 92%. Metabolism of finerenone is 90 % made by CYP3A4, with the remainder metabolised primarily by CYP2C8 to pharmacologically inactive metabolites. Excretion is 80 % in the urine with a half-life of 2-3 h. The most common adverse effect of finerenone is hyperkalaemia. However, it does not exhibit antiandrogenic side effects. In a program of clinical trials, it has demonstrated efficacy and safety in the treatment of chronic renal insufficiency in patients with type 2 diabetes.
Keywords: finerenone, diabetes type 2, chronic kidney disease, pharmacodynamics, pharmacokinetics.
Accepted: April 13, 2023; Published: April 21, 2023 Show citation
References
- Georgianos PI, Agarwal R. The Nonsteroidal Mineralocorticoid-Receptor-Antagonist Finerenone in Cardiorenal Medicine: A State-of-the-Art Review of the Literature. Am J Hypertens. 2023;36(3):135-143.
Go to original source... 
Go to PubMed... - Chung EY, Ruospo M, Natale P, Bolignano D, Navaneethan SD, Palmer SC, Strippoli GF. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2020; 10:CD007004. Go to original source... Go to PubMed...
- Grune J, Beyhoff N, Smeir E, et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018;71(4): 599-608. Go to original source... Go to PubMed...
- Gomez-Sanchez E, Gomez-Sanchez CE. The multifaceted mineralocorticoid receptor. Compr Physiol. 2014;4:965-994. Go to original source... Go to PubMed...
- Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, Zannad F. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J. 2021;42(2):152-161. Go to original source... Go to PubMed...
- Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol. 2017;12(12):2032-2045. Go to original source... Go to PubMed...
- González-Juanatey JR, Górriz JL, Ortiz A, Valle A, Soler MJ, Facila L. Cardiorenal benefits of finerenone: protecting kidney and heart. Ann Med. 2023;55(1):502-513. Go to original source... Go to PubMed...
- SPC Kerendia. Verze z 1. 3. 2023, dostupné na www.sukl.cz.
- Heinig R, Gerisch M, Engelen A, Nagelschmitz J, Loewen S. Pharmacokinetics of the Novel, Selective, Non-steroidal Mineralocorticoid Receptor Antagonist Finerenone in Healthy Volunteers: Results from an Absolute Bioavailability Study and Drug-Drug Interaction Studies In Vitro and In Vivo. Eur J Drug Metab Pharmacokinet. 2018;43(6):715-727. Go to original source... Go to PubMed...
- Gerisch M, Heinig R, Engelen A, Lang D, Kolkhof P, Radtke M, Platzek J, Lovis K, Rohde G, Schwarz T. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro. Drug Metab Dispos. 2018;46(11):1546-1555. Go to original source... Go to PubMed...
- Heinig R, Fricke R, Wertz S, Nagelschmitz J, Loewen S. Results From Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Inhibitory Effect of Finerenone on the Drug Transporters BCRP, OATP1B1, and OATP1B3. Eur J Drug Metab Pharmacokinet. 2022;47(6):803-815. Go to original source... Go to PubMed...
- Heinig R, Gerisch M, Bairlein M, Nagelschmitz J, Loewen S. Results from Drug-Drug Interaction Studies In Vitro and In Vivo Investigating the Effect of Finerenone on the Pharmacokinetics of Comedications. Eur J Drug Metab Pharmacokinet. 2020;45(4):433-444. Go to original source... Go to PubMed...
- Agarwal R, Anker SD, Bakris G, et al. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone. Nephrol Dial Transplant. 2022;37(6):1014-1023. Go to original source... Go to PubMed...
- Bakris GL, Agarwal R, Chan JC, et al. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial. JAMA. 2015;314(9):884-894. Go to original source... Go to PubMed...
- Bakris GL, Agarwal R, Anker SD, et al. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. N Engl J Med. 2020;383(23):2219-2229. Go to original source... Go to PubMed...
- Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes. N Engl J Med. 2021;385(24):2252-2263. Go to original source... Go to PubMed...